Panobinostat, a histone deacetylase inhibitor, rescues the angiogenic potential of endothelial colony-forming cells in moyamoya disease release_5o7uadtby5f23canm2s32he5my

by Anshika Jangra, Seung Ah Choi, Eun Jung Koh, Youn Joo Moon, Kyu-Chang Wang, Ji Hoon Phi, Ji Yeoun Lee, Seung-Ki Kim

Published in Child's Nervous System by Springer Nature.

2019   Volume 35, Issue 5, p823-831


Moyamoya disease (MMD) is one of the most common causes of pediatric stroke. We found defective angiogenic function and downregulation of retinaldehyde dehydrogenase 2 (RALDH2) in MMD endothelial colony-forming cells (ECFCs). Downregulation of RALDH2 mRNA was caused by decreased binding of acetyl-histone H3 (Ac-H3) to the RALDH2 promoter. In this study, we evaluated the feasibility of using a histone deacetylase (HDAC) inhibitor, panobinostat, to upregulate RALDH2 expression and restore the angiogenic potential of MMD ECFCs.
In text/plain format

Archived Content

There are no accessible files associated with this release. You could check other releases for this work for an accessible version.

"Dark" Preservation Only
Save Paper Now!

Know of a fulltext copy of on the public web? Submit a URL and we will archive it

Type  article-journal
Stage   published
Date   2019-02-27
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0256-7040
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 8f2013d1-6520-4c1b-8d31-547e0a512ca2